,
your personalized virtual assistant to find clinical trials. Go head, 
Mary-Ellen Taplin, MD
Dana-Farber Cancer InstituteBoston, Massachusetts - 02115 Dana-Farber/Harvard Cancer Center at Dana ...Boston, Massachusetts - 02115 (617-632-4001) |
- CLINICAL TRIALS 7
- CONDITIONS5
- INTERVENTIONS17
- SINCE2008
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
October 2009 - July 2012
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases
September 2009 - April 2010
Ketoconazole Hydrocortisone Dutasteride and Lapatanib (KHAD-L) in Prostate Cancer
August 2009 - August 2011
Avastin Docetaxel and Androgen Deprivation Followed by Continued Avastin and Androgen Deprivation for Men With a Rising PSA After Local Therapy
April 2008 - April 2011
Metformin in Castration-Resistant Prostate Cancer
September 2010 - September 2012
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
October 2008 - August 2011
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
September 2009 - December 2010
Prostatic Neoplasms
Neoplasm Metastasis
Bone Neoplasms
Bone Marrow Diseases
Recurrence
Bevacizumab
Docetaxel
Dasatinib
Avastin
Dutasteride
Bicalutamide
Leuprolide Acetate
Hydrocortisone
Imaging Biomarker Analysis
Metformin
Tok-001
Ketoconazole
Fluorine F 18 Sodium Fluoride
Lapatanib
Lupron Or Zoladex
Androgen Deprivation Therapy
Abiraterone Acetate Plus Leuprolide Acetate Plus Prednisone
